Drug Candidate for Treatment of Pain
Olorinab (APD371) is an oral, peripherally acting, highly-selective, full agonist of the cannabinoid receptor 2 (CB2). Olorinab is an internally discovered investigational drug candidate that Arena is exploring for development in several indications, with an initial focus on visceral pain associated with gastrointestinal disorders. This compound, through its selectivity for CB2, versus CB1, is designed to provide pain relief without psychoactive adverse effects.
We have completed a randomized, open-label Phase 2a clinical trial to evaluate the safety, tolerability and pharmacokinetics of two dose levels of olorinab for abdominal pain associated with Crohn’s disease. The CAPTIVATE Phase 2b trial for the treatment of abdominal pain associated with IBS has been initiated.
|Drug Candidate||Disease Area||Target||Status||Retained Rights|
|Olorinab (APD371)||GI Pain||CB2 Agonist||Phase 2b ongoing||Worldwide|
|Drug Candidate||Olorinab (APD371)|
|Disease Area||GI Pain|
|Status||Phase 2b ongoing|
Olorinab (APD371) has not been approved by the US Food and Drug Administration or any other regulatory agency.
Last updated as of 8/7/19